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Objective: To determine the values, beliefs, and attitudes that influence
a man’s intention to undergo or defer genetic testing for prostate can-
cer risk.
Design: Qualitative, using focus group interviews – 12 focus groups
were conducted to identify key values and beliefs about genetic testing
for prostate cancer risk in anticipation of its future availability.
Setting: Medium-sized, mid-west, US city.
Participants: Community sample of 90 lay men of diverse educational,
ethnic, and age backgrounds.
Analysis: Descriptive statistics and immersion/crystallization to identify
themes and sub-themes.
Results: The major areas of concern were distilled into the following
themes: beliefs about consequences, expectations, benefits for patients,
beliefs about barriers, and susceptibility concerns.
Conclusion: Identifying these men’s values will help health professionals
anticipate the informational and ethical needs of patients in the in-
formed consent process. Men will need to understand how such testing
may affect their planning regarding future prostate health, and how
medical information is used outside of the physician–patient relation-
ship.
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As molecular genetic technologies are used to in-
vestigate genetic factors that predispose men for
prostate cancer risk (e.g., the hereditary prostate
cancer 1, or HPC1, gene), there is a corresponding
need to understand patients’ values and beliefs
about such screening. Genetic testing for prostate
cancer risk of presymptomatic men holds the
promise of becoming an important tool in combat-
ing prostate cancer. Yet, its appropriate use is not
well understood by patients or the majority of
health care professionals to whom they will turn
for assistance. Understanding the motivations of
men who may one day consider genetic screening
for prostate cancer will allow for anticipation of
their goals, concerns, fears, and objections when
testing becomes available. This process can help
physicians and other health professionals 1) coun-
sel men and families about the risks and benefits of
testing, 2) assist patients in overcoming irrational
fears, and 3) facilitate provider respect for reasons
leading to refusal.
While prostate cancer has been shown to have a
genetic component, the degree of genetic versus
environmental factors influencing cancer develop-
ment is uncertain (1). Although many are trying to
identify the HPC1 gene on both chromosome 1
and chromosome X, there are conflicting data as to
its contribution to inherited forms of prostate can-
cer (2). It is likely that there will be more than one
HPC gene – similar to the situation in other com-
mon solid tumors such as breast and colorectal
cancer (3–6). The extent of the impact of environ-
mental factors in the development of prostate can-
cer is open to question (7, 8). As the gene loci for
prostate cancer are identified in the near future, it
is likely that genetic testing for prostate cancer risk
will be developed for the research setting.
As is being seen for breast cancer and colorectal
cancer, genetic screening for prostate cancer risk
will eventually move from the research to the clini-
cal setting. Barring any technological barriers, the
identification of these mutations may then eventu-
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ally lead to a screening test for the non-research
setting. Once screening is possible, it may have the
potential use of identifying higher risk men need-
ing increased or earlier initiation of surveillance.
Testing positive for HPC may convey a higher risk
of earlier onset and/or increased aggressiveness
and metastasis, or instead may help clinicians iden-
tify those groups of men who would best benefit
from specific treatments for prostate cancer. Thus,
genetic screening for prostate cancer risk may help
men in their decision between watchful waiting and
a more aggressive approach to treatment when
early prostate cancer is discovered.
The advent of genetic testing for prostate cancer
risk will require efforts to educate both patients
and professionals. An understanding of men’s per-
spectives on the prospect of genetic testing for
prostate cancer risk is crucial to the development
of protocols for education/counseling and insuring
informed consent. This testing may one day be
used as a tool for identifying genetic prostate can-
cer risk (GPCR), but how will men respond to the
opportunity to be tested and why? While surveys
of preferences for or against such testing have been
performed (identifying support for testing as high,
74–91%), the motivations from the patient’s per-
spective have not been evaluated (9–11). One
study did ascertain that perceived risk, emotional
distress, and concern about treatment side-effects
were predictors of intention to test (11). However,
no study to date has yet undertaken comprehensive
evaluation of the spectrum of values that may
influence one’s decision to pursue genetic testing
for prostate cancer risk.
The ambiguity of the multi-factorial nature of
prostate cancer, as well as how to respond to a
positive test, may ultimately present a quandary to
the patient. The efficacy of existing treatment op-
tions is not well established and the risks of treat-
ment include incontinence and impotence (12, 13).
Many of the concerns in prostate cancer revolve
around the concept of quality of life, a topic of
pertinent consideration in prostate cancer screen-
ing (14–18). The decision to test for genetic risk
initiates a set of decisions that must be based on
knowledge that is inherently uncertain. The ethical
response to such uncertainty is relevant, in that the
weighing of benefit and personal choice consider-
ations are not clear-cut when the benefit to the
patient is indeterminate (19–22). A critical omis-
sion in the theoretical discourse on the conse-
quences of genetic screening has been in
understanding the values of those who would be
most affected – patients. In formulating a clinical
plan, health providers should incorporate relevant
values of the patient, as required by the ethical
principle of respect for autonomy (23).
An understanding of the values that men hold
toward prostate cancer genetic screening would
facilitate medical decision making in both the pri-
mary care and referral-based settings. Even if pre-
dictive testing will be made available to the public
through speciality clinics, one must not overlook
the eventual delivery of such services in the pri-
mary care setting, patients’ initial requests for in-
formation and guidance concerning discussions of
testing are likely to occur in primary care settings.
Such forces may be exerted particularly if costs of
genetic testing fall and make primary care genetic
testing economically feasible. Hence, a thorough
understanding of the values of men from the gen-
eral population toward prostate cancer genetic
screening would facilitate medical decision making
in both the primary care and referral-based set-
tings. We hypothesize that a man’s beliefs,
attitudes, social influences, and demographic char-
acteristics will be salient in decision making on
genetic screening for prostate cancer risk. This
study seeks to identify the core values, beliefs,
attitudes, and intended behaviors about prostate
cancer genetic screening, with subsequent evalua-
tion of men to quantify these data. Hence, this
study is a ‘first look’ at the themes that men may
hold toward genetic testing for prostate cancer
risk. The development of a conceptual map of the
moral, cultural, and other values important to the
lay person in prostate cancer genetic screening is
the goal of this project. These results should in-
form counseling and public policy for primary care
genetic screening – particularly regarding disclo-
sure needs in the informed consent process.
Method
Design
We conducted 12 focus groups with a total of 90
men from the general population, aged 18–70
years of age, excluding men who have or have had
cancer. Within this group, men with positive fam-
ily histories of prostate cancer were not excluded.
We used focus groups to identify a broad spectrum
of values, beliefs, social influence factors, and atti-
tudes that were relevant to participants regarding
prostate cancer genetic screening. Focus groups
have been used in the past in marketing research,
but the methodology is finding increased applica-
tion as a means of refining hypotheses and insuring
content validity of survey instruments throughout
the social sciences (24–29). Persons are assembled
to discuss a specific topic under the auspices of a
moderator, who asks a series of probe questions.
The respondents then offer their own insights and
build upon the comments of the other participants
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in the group. The project was conducted at the
University of Michigan, and approved by the UM
Institutional Review Board prior to any human
subject’s activity (c1998-028).
Instrument development
We began with a systematic literature review of the
lay (newspaper and magazine articles), medical,
and bioethics literature on prostate cancer regard-
ing genetic testing and genetic counseling from
Medline and Bioethicsline. A list of relevant moral,
cultural, and other themes concerning genetic test-
ing for prostate cancer was generated from these
articles. The list facilitated development of a dis-
cussion guide of 35 probe and broad open-ended
questions for the focus groups (available on re-
quest). The primary variables of interest included
subjects’ values and attitudes about genetic screen-
ing for prostate cancer risk for them; their experi-
ence with prostate cancer in family members and
friends; the motivating factors to accept and to
refuse genetic testing for prostate cancer risk; and
their views on the consequences for such testing.
The discussion guide was refined after the first
focus group. A short demographics instrument
(not linked for identification to the subjects) as-
sessed age, race, ethnic, cultural background, in-
surance status, and prior health history.
Participants
A research firm specializing in the conduct of focus
groups on health topics, Personal Touch Market-
ing, was hired to recruit participants, assist in the
development of the discussion guide, and moderate
the focus groups. All groups were moderated by
the same Caucasian male who identified himself as
an employee of Personal Touch Marketing, con-
tracted to conduct the focus groups from the local
University. We recruited a total of 12 groups of
men, and set up groups in proportion with the area
population with eight Caucasian groups, separat-
ing groups by education (greater or less than 2
years of college) and age (18–39, 40–54, 55–70),
with three African-American groups varying by
age (18–39, 40–54, 55–70) and all educational
backgrounds, and one Asian/Asian-American
group, ages (18–70) and all educational back-
grounds. A panel of men who identified themselves
as willing to participate in focus groups to discuss
‘men’s health issues’ was recruited through adver-
tisements in local newspapers, and in posted no-
tices at local churches, markets, and restaurants.
Respondents to these notifications were screened
by telephone, and those men meeting eligibility
criteria were consecutively placed into groups ac-
cording to stratification criteria. As this study
sought the values of non-high risk men from the
primary care setting, men with a history of
prostate cancer or other cancer were excluded from
participation. Each focus group lasted 2 h.
The participants signed an Institutional Review
Board-approved written informed consent form
before their participation. At the beginning of each
group, participants viewed an educational video on
the nature of genetic testing for prostate cancer
risk. The video was designed with a neutral tone to
minimize biases of participants for or against ge-
netic testing for prostate cancer risk (transcript
available on request). It briefly explained the loca-
tion and function of the prostate, the concept of
prostate cancer, and current screening options, and
the available treatments for prostate cancer – with
their attendant ambiguity of efficacy compared to
non-treatment, as well as side-effects such as impo-
tence, incontinence, and radiation proctitis. While
obviously not as comprehensive as a genetics coun-
seling session, this tape provided a common, palat-
able informational foundation for all subjects to
discuss in the focus groups. The tape then de-
scribed the likely availability of genetic testing for
prostate cancer risk in the future, and the uncer-
tainty about how this test would assess the risk or
aggressiveness of future emergence of cancer. This
method promoted interaction of the focus group
members, thereby catalyzing increased individual
reflection on screening benefits and consequences.
The moderator then used the interview guide to
elicit the broad spectrum of values, beliefs, and
attitudes that were relevant to participants regard-
ing prostate cancer genetic screening. The discus-
sion involved a lively interchange of questions and
concerns on the utility and consequences of genetic
screening for prostate cancer. Each participant
completed a brief demographics questionnaire.
Subjects were compensated for their participation
with a stipend of $50 for their time and travel.
The proceedings of all groups were audio-
recorded and subsequently transcribed. The result-
ing transcripts were analyzed using the techniques
of immersion and crystallization to ascertain rele-
vant themes regarding how screening is viewed,
how screening can be prepared for, and how test
results could be discussed (29). For the analysis,
each investigator read the transcripts multiple
times and independently identified major themes
and sub-themes. These themes and sub-themes
were discussed as a group to develop a conceptual
map of themes and sub-themes that incorporated
each investigator’s input. Differences in interpreta-
tion were minimal and readily negotiated.
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The themes identified during the focus groups
were mailed to the original participants to conduct
verification, a process of evaluating the accuracy of
qualitative analysis (30). The themes were con-
verted to a narrative format to facilitate partici-
pants’ understanding. Forty-two of the 90
participants returned the feedback form, voicing
support of the statements in the feedback form and
provided further details on some statements. These
additional data revealed the diversity of values in
the various groups, and highlighted some of the
differences that arose between ethnic groups. Some
indicated they did not identify with some state-
ments made by members of other ethnic groups,




Participants ranged from 18 to 70 years of age.
While most were married, single and divorced/sep-
arated men were well represented. Most partici-
pants were Caucasian, had more than 2 years of
college education, and no family history of
prostate cancer.(Table 1) Most men who voiced a
preference appeared to be favorably disposed to-
ward genetic testing for prostate cancer risk, with
increased support voiced by older men. For focus
groups with men over 40, the majority had a
physical with a digital rectal exam and/or prostate
specific antigen (PSA) test in the previous 2 years.
Themes
The main themes that arose addressed the follow-
ing issues (Table 2):
 Beliefs about consequences,
 Expectations,
 Benefits for patients,
 Beliefs about barriers, and
 Susceptibility concerns.
As seen in Table 2, each major theme comprised
several sub-themes that captured positive and neg-
ative evaluative moral, pragmatic, and consequen-
tialist concerns of participants’ about prostate
cancer genetic testing.
The first theme of Beliefs about consequences
concerns the ability to obtain health and life in-
surance if one were to test positive for increased
GRPC. Men wondered if they would have to con-
tinue to receive other forms of screening (e.g.,
PSA, digital rectal exam, and ultrasound) if they
were to test GRPC-negative. They were curious
about how to best follow up for a GRPC-positive
result. Given the ongoing development of genetics
research, subjects thought that further genetic test-
ing may be still required in the future, regardless of
their test results. One fear voiced was that they
could lose their job or not get promoted if they
tested GRPC-positive. Such test results could then
result in stigmatization by other family members
and by society at large. This concern seemed par-
ticularly important to African-Americans. African-
Americans had increased suspicion regarding
confidentiality and concerns of how use of testing
results could be potentially abused. One prominent
concern among participants was how would one
break this ‘bad news’ to one’s family.
Many thought that patients who test GRPC-
positive may be pressured to receive some sort of
treatment before cancer actually occurs. This fear
was coupled with that of compulsory testing (for
insurance or employment), and that they might not
want such testing, especially given these conse-
quences. However, some believed that compulsory
testing could be helpful for employees because it
would encourage more preventive care. Some
thought it would be better to know one’s test
results, as it could prompt one to follow a healthier

















2825Less than 2 years of college
72Greater than 2 years of college 65
Family history of prostate cancer
8Yes 9
No 82 91
Insurance type (multiple responses allowed, so total\100%)





Other insurance 5 6
Unsure 3 3
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Table 2. Major focus group themes and sub-themes
Beliefs about consequences...
 On insurability
 Will have to continue other forms of prostate testing
May need further genetic testing as technology develops
Employment/ability to get promoted could be affected
Stigmatization of myself
 How will I tell my family?
Pressure to receive treatment
Fear of compulsory testing
Compulsory testing may be helpful for employees and lead to
more preventative care
Truth of knowing test results is good
Could a positive test lead to precipitous action (for example, pro-
phylactic surgery)?
Non-traditional health measures may be helpful
Expectations...
 Who pays for this? (i.e., HMO/Insurance Co., but not me)
If no cure currently, why get test?
 If it doesn’t detect current cancer, why get the test?
 If a positive test, I can prevent disease by lifestyle changes
Medical science will find a cure




 Society/medical science helped through testing
Truth of knowing what is good
May expedite finding a cure
It could save my life
It will give me peace of mind
Knowledge could help other family members




 No curative treatment
 Treatment for cancer will hurt my sex life
Unnecessary surgery will result
 Lack of knowledge
Decreased quality of life may result
Accuracy problems of testing
Self-treatment (such as lifestyle changes) are better than physician
treatment
Confidentiality
Creates worry, anxiety and stress
Procrastination could delay testing
Could this knowledge be used for social or political ends?
Susceptibility concerns...
Family history
Current/past behaviors affect susceptibility
Ethnic background
The second theme of Expectations comprises
practical concerns about the repercussions of test-
ing GRPC-positive. The men, on the whole, felt
strongly that testing should be a covered benefit
under health insurance. Their opinion seemed
grounded in a concern that this test should not be
cost-shifted to them. Some pragmatic concerns
arose as to how useful the test would be when
there is no definitive cure, and since this testing
would not detect current cancer. Again, men
wanted to know if testing would result in dietary
and exercise-based responses on their part to mini-
mize their risk. Men were hopeful that widespread
testing might help to better understand prostate
cancer, and lead to its cure. They were concerned
about whether they would be seen by their family
physician for testing, with many perceiving that
they may have to go to a geneticist. Some were not
aware that this may be necessary (and some stated
this was unwanted) and others were surprised
about having to undergo any form of genetic coun-
seling. Some men of Asian decent voiced interest in
genetic testing for all employees based on an obli-
gation of corporations to maintain employee
health.
The third theme is Benefits for patients. Antici-
pated benefits were the basis for many to voice
their support for genetic testing for prostate cancer
risk. The cost of genetic testing was thought (or
hoped) to be low. They envisioned that such test-
ing would be helpful in considerations of family
planning, with some stating that if they were still
of procreative age, that a positive test may make
them pause in having children. Many thought that
testing would be helpful to society (in expediting a
cure), and also a personal good (in easing their
anxiety and leading to their own cure). Further,
many respondents mentioned the good of helping
other family members. In turn, greater emphasis
will be made on preventive screening tests to re-
duce the likelihood of cancer.
Many concerns were raised by respondents that
were included under the theme of Beliefs about
barriers. As noted in the first theme, men voiced
considerable consternation because of possible loss
of insurability if they tested GRPC-positive. They
feared that their ability to get or keep both life and
health insurance could become compromised as a
result of this information being shared with third
parties. Confidentiality concerns were prevalent
with all men, whether regarding their insurance,
their employers or their families. They were con-
cerned that the price of treatment would be too
high if their own insurance would not cover test-
ing. The lack of a definitive cure for prostate
cancer made some reluctant to pursue testing.
lifestyle through the ‘control’ of prostate cancer
risk factors, e.g., pursuing a low-fat diet and in-
creasing exercise. Others believed that being
GRPC-positive could lead to precipitous action,
e.g., prophylactic surgery. Some also thought that
such testing could promote use of non-traditional




They also expressed beliefs that, if they tested
GRPC-positive, treatment for cancer would hurt
their sex life and could result in unnecessary
surgery. These consequences could then cause de-
creased quality of life whether through an adverse
treatment outcome, or from the anxiety of a possi-
ble cancer outbreak. Some thought that the cre-
ation of worry, anxiety and stress might make
testing not worth the effort of combating cancer.
Many men thought that lack of knowledge of
genetic testing would result in fewer men seeking it.
Some wondered if accuracy problems of testing
could make the information less valuable, and
questionable in its utility. Also, many thought that
procrastination could delay men seeking testing. If
one tests positive, some thought that self-treatment
(such as lifestyle changes) are better than physician
treatment. One concern of African-Americans
reflected on abuse of the sickle cell screening pro-
grams of years past, and some participants won-
dered if genetic testing results could be used for
larger social or political ends.
The last theme, Susceptibility concerns, describes
how much these men perceived themselves at risk.
Men who had a family history of prostate cancer,
(or any form of cancer) did perceive that they were
at higher risk than the average man. Men who had
previous, non-cancer related prostate problems
(such as benign prostatic hypertrophy and pro-
statitis) also thought they were at higher risk.
African-American men acknowledged their higher
risk, and some wondered if this was due to diet or
some other non-genetic factor. On the whole,
African-American men were less enthusiastic about
testing.
Discussion
Those who voiced a preference appeared to sup-
port genetic testing for prostate cancer risk, with
less support among African-Americans. Previous
experience in both breast and colorectal cancer,
though, have revealed that people often have initial
high interest in testing when posed conceptually,
but that the fall off from testing intention to get-
ting a test drawn, and receiving the results, is
dramatic, secondary to psychological and other
concerns (31–33). In this qualitative investigation,
intention to test was not the endpoint. Rather, an
understanding of the spectrum of values that
would influence their decision making for testing
was the goal. Indeed, although the benefits and the
disadvantages of genetic screening for prostate
cancer risk are yet to be clarified, these men viewed
genetic testing with considerable naivete. Concepts
of risk, cost and perceptions of benefit revealed a
lack of sophistication about prostate cancer, and
biases about how they think it can be somehow
prevented. Concerns about others family members,
a common primary concern in other genetic testing
paradigms, was somewhat less prominent in these
data, though noted by respondents. Of note, men
seemed less concerned about concurring with their
spouses’ view on genetic testing, than following the
counsel of their primary care physician.
By understanding the motivations of why men
would want such screening and what barriers
might preclude them, an informed consent process
can be designed to educate men about the many
influencing factors relevant to their informed
choice. Even so, the factors that ultimately predict
getting tested may be different than those ex-
pressed in this study. These data then highlight the
following particular needs: 1) detailed education
on prostate cancer and testing prior to genetic
testing and counseling; 2) understanding concepts
of risk and ambiguity regarding the interpretation
of genetic test results and; 3) high quality pre- and
post-test educational counseling.
The next phase of this research will quantita-
tively evaluate the values of men toward testing
intention, and the measurement of the relative im-
portance of each of these values. When, how and
why men may or may not be receptive to prostate
cancer genetic screening is likely to vary according
to an individual’s beliefs, attitudes, social influ-
ences, and demographic characteristics. Under-
standing how these factors are relevant to genetic
screening decision making will help physicians and
genetic counselors to tailor the informed consent
process to the needs of their patients.
There were several limitations of this research.
Self-selection bias of the recruiting approach used
would likely favor men most interested in their
health and prevention, a factor that may have
biased them towards screening. Also, these subjects
live in close proximity to a tertiary medical center
known for its genetics research. Their attitudes
toward genetic screening could be biased as a re-
sult of local media attention. Further, qualitative
research is geared toward describing a spectrum of
attitudes, rather than serving to describe the preva-
lence of opinions. This type of research does not
allow for linking demographic characteristics of
subjects to their responses, statistical analysis, or
rank ordering of the themes. As noted above,
future quantitative research will address these ar-
eas of interest. Lastly, this study did not endeavor
to see how men’s attitudes might be shaped by the
method of intervention (as was noted in a previous
study by Bekker et al.) (34). Such interventions
may be possible with a larger sample population in
future research.
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Conclusions
Most, but not all, men in this study were very
favorably disposed to genetic testing for prostate
cancer risk. Further, this attitude appeared to be
age related, i.e., increased support with age, and
there are ethnic differences regarding the degree of
suspicion with which men view such testing, i.e.,
increased with African-Americans and decreased
among Asian men. Men will require considerable
education to prepare them for genetic testing for
prostate cancer risk. While these men have con-
cerns about discrimination and negative social con-
sequences that have proven important in women
contemplating genetic testing for breast cancer
risk, they also seem distinctly more pragmatic and
less family-oriented in their thinking. Further re-
search is now needed to examine quantitatively the
relative importance of the identified factors as pre-
dictors that encourage or discourage men from
obtaining genetic testing for prostate cancer risk.
These results suggest that there are important age,
ethnicity and co-morbidity predictors that merit
further inquiry.
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